Genetic polymorphisms of key enzymes in folate metabolism affect the efficacy of folate therapy in patients with hyperhomocysteinaemia. Issue 8 (12th April 2018)

• Record Type: Journal Article
• Authors: Du, Binghui; Tian, Huizi; Tian, Dandan; Zhang, Chengda; Wang, Wenhua; Wang, Lianke; Ge, Mengying; Hou, Quanliang; Zhang, Weidong
• Is Part Of: British journal of nutrition. Volume 119:Issue 8(2018)
• Page Start: 887
• Page End: 895
• Publication Date: 2018-04-12
• Subjects: Hyperhomocysteinaemia, -- Folate, -- Efficacy, -- Gene polymorphisms; Nutrition -- Periodicals; 572.4
• DOI: 10.1017/S0007114518000508
• Languages: English
• ISSNs: 0007-1145

Abstract

Abstract: The aim of this study is to analyse the efficacy rate of folate for the treatment of hyperhomocysteinaemia (HHcy) and to explore how folate metabolism-related gene polymorphisms change its efficacy. This study also explored the effects of gene–gene and gene–environment interactions on the efficacy of folate. A prospective cohort study enrolling HHcy patients was performed. The subjects were treated with oral folate (5 mg/d) for 90 d. We analysed the efficacy rate of folate for the treatment of HHcy by measuring homocysteine (Hcy) levels after treatment. Unconditioned logistic regression was conducted to analyse the association between SNP and the efficacy of folic acid therapy for HHcy. The efficacy rate of folate therapy for HHcy was 56·41 %. The MTHFR rs1801133 CT genotype, TT genotype and T allele; the MTHFR rs1801131 AC genotype, CC genotype and C allele; the MTRR rs1801394 GA genotype, GG genotype and G allele; and the MTRR rs162036 AG genotype and AG+GG genotypes were associated with the efficacy of folic acid therapy for HHcy ( P <0·05). No association was seen between other SNP and the efficacy of folic acid. The optimal model of gene–gene interactions was a two-factor interaction model including rs1801133 and rs1801394. The optimal model of gene–environment interaction was a three-factor interaction model including history of hypertension, history of CHD and rs1801133. Folate supplementation can effectively decrease Hcy level. However, almost half of HHcy patients failed to reach the normal range. The efficacy of folate therapy may be genetically regulated.